UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 237.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,377,517 shares of the company’s stock after purchasing an additional 2,376,668 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Teva Pharmaceutical Industries were worth $60,863,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in TEVA. Public Sector Pension Investment Board boosted its holdings in shares of Teva Pharmaceutical Industries by 23.4% in the third quarter. Public Sector Pension Investment Board now owns 580,967 shares of the company’s stock worth $10,469,000 after buying an additional 110,300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Teva Pharmaceutical Industries by 3.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 453,251 shares of the company’s stock worth $8,168,000 after acquiring an additional 14,372 shares during the last quarter. BNP Paribas grew its position in shares of Teva Pharmaceutical Industries by 1,031.1% during the 3rd quarter. BNP Paribas now owns 7,918 shares of the company’s stock valued at $143,000 after acquiring an additional 7,218 shares during the period. Blueshift Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $740,000. Finally, Bridgewater Associates LP raised its holdings in Teva Pharmaceutical Industries by 5.2% in the 3rd quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock worth $418,000 after purchasing an additional 1,144 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $16.65 on Tuesday. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The stock has a market capitalization of $18.86 billion, a price-to-earnings ratio of -19.59, a PEG ratio of 1.30 and a beta of 0.87. The company has a fifty day moving average of $17.54 and a 200 day moving average of $17.36. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31.

Analyst Ratings Changes

TEVA has been the subject of several recent research reports. Barclays boosted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.